Early Patient Access Treatment Use Protocol CA204-220
Status:
Available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this expanded access program is to provide treatment with elotuzumab in
combination with lenalidomide and dexamethasone for patients with relapsed or refractory
multiple myeloma at Japanese sites where licensed physicians determine clinical need.